BURLINGTON – If you’re interested in participating in a clinical trial to solve some of the riddles of COVID-19, LabCorp can help you make that connection.
The Burlington-based corporation’s Covance drug development business has created COVID-19 Clinical Trial Connect in the U.S., a website designed to help people find information about how they can take part in coronavirus research.
“Our goal is to link people interested in these clinical trials with sponsors so that together we may find solutions for this global pandemic,” said Michael Brooks, Covance’s president of Clinical Development and Commercialization Solutions.
Brooks pointed out that hundreds of COVID-19-related clinical trials are already underway or will begin soon. Access the Clinical Trial Connect site and you can be notified of studies run by Covance for the pharmaceutical industry, as well as those included in clinicaltrials.gov, a database of privately and publically funded clinical studies. Patients can register if they’d like to participate.
Covance said trial opportunities are diverse and sponsors are recruiting patients who have COVID-19, who may have recovered from the virus, or who may simply have been exposed.
“With our COVID-19 Clinical Trial Connect, we’re helping bridge the gap,” Brooks added. “Patients who choose to participate in a clinical trial are true medical heroes. We are thrilled to have the capacity to directly engage with patients who would not otherwise be aware of ongoing trials and give them the opportunity to consider participation, particularly at this time.”
LabCorp, founded almost 51 years ago in Burlington, operates one of the largest clinical laboratory networks in the world. It is an $11.5 billion business with more than 65,000 employees. Covance is a global contract research organization that, according to its website, has worked on all of the top 50 best-selling drugs available today through its full spectrum of nonclinical, clinical and commercialization services.
(c) North Carolina Biotechnology Center
Original Article Source: WRAL TechWire